Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
3.12
USD
|
+0.65%
|
|
-12.11%
|
-57.26%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,261
|
880.2
|
617.3
|
307.5
|
132.4
|
-
|
-
|
Enterprise Value (EV)
1 |
927.3
|
538.3
|
273.3
|
83.92
|
-110.5
|
-116.9
|
-82
|
P/E ratio
|
-12.9
x
|
-7.45
x
|
-21.3
x
|
-3.27
x
|
-1.38
x
|
-0.96
x
|
-1.01
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9,341
x
|
116
x
|
4.68
x
|
6.01
x
|
2.21
x
|
11.9
x
|
3
x
|
EV / Revenue
|
6,869
x
|
70.8
x
|
2.07
x
|
1.64
x
|
-1.85
x
|
-10.5
x
|
-1.86
x
|
EV / EBITDA
|
-17.4
x
|
-5.02
x
|
-15.3
x
|
-0.73
x
|
0.96
x
|
0.64
x
|
0.67
x
|
EV / FCF
|
-119
x
|
-6.15
x
|
-976
x
|
-0.65
x
|
1.73
x
|
0.91
x
|
0.63
x
|
FCF Yield
|
-0.84%
|
-16.3%
|
-0.1%
|
-154%
|
57.9%
|
110%
|
159%
|
Price to Book
|
4.41
x
|
3.06
x
|
2.21
x
|
1.45
x
|
0.49
x
|
0.9
x
|
1.47
x
|
Nbr of stocks (in thousands)
|
36,765
|
41,735
|
41,962
|
42,130
|
42,445
|
-
|
-
|
Reference price
2 |
34.30
|
21.09
|
14.71
|
7.300
|
3.120
|
3.120
|
3.120
|
Announcement Date
|
3/4/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.135
|
7.6
|
131.8
|
51.13
|
59.87
|
11.16
|
44.19
|
EBITDA
1 |
-
|
-53.4
|
-107.2
|
-17.82
|
-114.3
|
-115.3
|
-182.4
|
-122
|
EBIT
1 |
-
|
-54.3
|
-108.7
|
-19.8
|
-116.2
|
-109.7
|
-167.2
|
-156.6
|
Operating Margin
|
-
|
-40,223.7%
|
-1,429.74%
|
-15.02%
|
-227.3%
|
-183.14%
|
-1,498.26%
|
-354.34%
|
Earnings before Tax (EBT)
1 |
-
|
-54.74
|
-108.6
|
-13.9
|
-103.2
|
-100.3
|
-168.1
|
-154.5
|
Net income
1 |
-27.22
|
-53.42
|
-106.9
|
-29.05
|
-93.8
|
-101
|
-168.1
|
-154.5
|
Net margin
|
-
|
-39,568.15%
|
-1,406.68%
|
-22.03%
|
-183.44%
|
-168.64%
|
-1,506.38%
|
-349.54%
|
EPS
2 |
-
|
-2.660
|
-2.830
|
-0.6900
|
-2.230
|
-2.264
|
-3.266
|
-3.090
|
Free Cash Flow
1 |
-
|
-7.805
|
-87.49
|
-0.28
|
-129.1
|
-64
|
-128
|
-130
|
FCF margin
|
-
|
-5,781.48%
|
-1,151.13%
|
-0.21%
|
-252.47%
|
-106.89%
|
-1,146.9%
|
-294.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/29/20
|
3/4/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
6.877
|
0.408
|
0.679
|
112.5
|
18.2
|
5.678
|
30.25
|
2.159
|
13.05
|
52.4
|
2.583
|
2.567
|
2.9
|
3.352
|
3.352
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-28.73
|
-34.83
|
-38.73
|
73.4
|
-19.63
|
-34.68
|
-12.26
|
-38.42
|
-30.87
|
10.82
|
-39.78
|
-40.09
|
-40.5
|
-41.33
|
-41.96
|
Operating Margin
|
-417.83%
|
-8,536.52%
|
-5,704.57%
|
65.22%
|
-107.88%
|
-610.8%
|
-40.52%
|
-1,779.43%
|
-236.58%
|
20.64%
|
-1,539.89%
|
-1,561.94%
|
-1,396.42%
|
-1,233.09%
|
-1,252.02%
|
Earnings before Tax (EBT)
1 |
-28.7
|
-34.72
|
-38.06
|
75.52
|
-16.63
|
-31.32
|
-8.836
|
-35.18
|
-27.84
|
13.79
|
-36.05
|
-36.57
|
-37.26
|
-39.82
|
-40.89
|
Net income
1 |
-28.29
|
-34.76
|
-38.09
|
75.46
|
-31.66
|
-34.94
|
-11.95
|
-18.88
|
-28.03
|
13.16
|
-36.05
|
-36.57
|
-37.26
|
-39.82
|
-40.89
|
Net margin
|
-411.37%
|
-8,518.87%
|
-5,610.16%
|
67.05%
|
-173.96%
|
-615.38%
|
-39.49%
|
-874.43%
|
-214.84%
|
25.12%
|
-1,395.5%
|
-1,424.9%
|
-1,284.89%
|
-1,188.12%
|
-1,220.02%
|
EPS
2 |
-0.7100
|
-0.8300
|
-0.9100
|
1.710
|
-0.7500
|
-0.8300
|
-0.2800
|
-0.4500
|
-0.6700
|
0.3000
|
-0.8520
|
-0.8620
|
-0.8540
|
-0.9250
|
-0.9500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/5/22
|
8/4/22
|
11/9/22
|
2/28/23
|
5/9/23
|
8/9/23
|
11/9/23
|
2/28/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
334
|
342
|
344
|
224
|
243
|
249
|
214
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-7.81
|
-87.5
|
-0.28
|
-129
|
-64
|
-128
|
-130
|
ROE (net income / shareholders' equity)
|
-
|
-44.4%
|
-37.2%
|
-10.2%
|
-38.2%
|
-40.4%
|
-69.9%
|
-69.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
7.770
|
6.890
|
6.650
|
5.030
|
6.340
|
3.460
|
2.120
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
2.24
|
1.69
|
0.6
|
1.94
|
0.8
|
1
|
5
|
Capex / Sales
|
-
|
1,657.04%
|
22.24%
|
0.46%
|
3.79%
|
1.34%
|
8.96%
|
11.32%
|
Announcement Date
|
5/29/20
|
3/4/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
3.12
USD Average target price
15.33
USD Spread / Average Target +391.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -57.26% | 132M | | +67.53% | 62.86B | | -0.77% | 41.38B | | +45.66% | 40.38B | | -10.72% | 27.64B | | +13.30% | 26.46B | | -22.79% | 18.9B | | +4.70% | 12.67B | | +24.10% | 12.27B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|